LGALS3 and carcinoma: Our study demonstrated the following: (i) all the markers are expressed in both benign and malignant FPTLs, indicating that to date there is no reliable immunostain that can stand alone and resolve the issue, (ii) statistically significantly more frequent expression of HBME-1, CK19, Galectin-3 proteins in carcinomas as compared to benign FPTLs (p = <0.01), (iii) HBME-1 and Galectin-3 were the most sensitive markers for the diagnosis of malignant FPTLs (75%), and (iv) Galectin-3 was the most specific one (90.3%).